NextCure Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
NextCure's earnings have been declining at an average annual rate of -17.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 64.9% per year.
Wichtige Informationen
-17.8%
Wachstumsrate der Gewinne
2.3%
EPS-Wachstumsrate
Biotechs Wachstum der Industrie | 17.0% |
Wachstumsrate der Einnahmen | -64.9% |
Eigenkapitalrendite | -71.7% |
Netto-Marge | n/a |
Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Jul 17We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Mar 23We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Dec 09Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
Aug 23Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?
May 10We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17Aufschlüsselung der Einnahmen und Ausgaben
Wie NextCure Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Jun 24 | 0 | -61 | 17 | 47 |
31 Mar 24 | 0 | -64 | 19 | 48 |
31 Dec 23 | 0 | -63 | 20 | 48 |
30 Sep 23 | 0 | -66 | 21 | 49 |
30 Jun 23 | 0 | -70 | 22 | 51 |
31 Mar 23 | 0 | -70 | 21 | 51 |
31 Dec 22 | 0 | -75 | 22 | 54 |
30 Sep 22 | 0 | -74 | 22 | 92 |
30 Jun 22 | 0 | -73 | 21 | 78 |
31 Mar 22 | 0 | -73 | 21 | 53 |
31 Dec 21 | 0 | -69 | 21 | 50 |
30 Sep 21 | 0 | -68 | 20 | 0 |
30 Jun 21 | 0 | -66 | 20 | 0 |
31 Mar 21 | 0 | -63 | 18 | 12 |
31 Dec 20 | 22 | -37 | 17 | 0 |
30 Sep 20 | 24 | -32 | 16 | 0 |
30 Jun 20 | 26 | -24 | 13 | 0 |
31 Mar 20 | 27 | -18 | 12 | 0 |
31 Dec 19 | 6 | -34 | 10 | 0 |
30 Sep 19 | 4 | -30 | 8 | 0 |
30 Jun 19 | 3 | -27 | 6 | 0 |
31 Mar 19 | 1 | -24 | 4 | 0 |
31 Dec 18 | 0 | -23 | 3 | 0 |
Qualität der Erträge: NXTC is currently unprofitable.
Wachsende Gewinnspanne: NXTC is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: NXTC is unprofitable, and losses have increased over the past 5 years at a rate of 17.8% per year.
Beschleunigtes Wachstum: Unable to compare NXTC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: NXTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: NXTC has a negative Return on Equity (-71.72%), as it is currently unprofitable.